Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 1,408 Shares

Posted by Geri Gentry on Jun 25th, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bruce Booth sold 1,408 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $99.98, for a total value of $140,771.84. Following the completion of the transaction, the director directly owned 613,589 shares of the company’s stock, valued at approximately $61,346,628.22. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The stock was sold at an average price of $121.86, for a total transaction of $34,813,452.24.
On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.39, for a total value of $30,305,683.43.
On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The shares were sold at an average price of $100.51, for a total value of $13,540,707.20.
On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The shares were sold at an average price of $98.52, for a total transaction of $24,268,431.60.
On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.01, for a total transaction of $10,471,246.56.
On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total value of $9,496,316.98.
On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total value of $1,056,455.18.
On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The shares were sold at an average price of $103.75, for a total value of $3,299,042.50.
On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.08, for a total transaction of $9,008.00.
On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.96, for a total transaction of $530,764.00.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock traded up $16.59 during trading on Thursday, hitting $116.46. The company’s stock had a trading volume of 3,915,007 shares, compared to its average volume of 826,395. The stock has a 50-day moving average price of $84.43 and a two-hundred day moving average price of $82.12. Kymera Therapeutics, Inc. has a 52 week low of $36.65 and a 52 week high of $130.05. The stock has a market cap of $9.58 billion, a price-to-earnings ratio of -32.62 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter in the prior year, the firm posted ($0.82) earnings per share. The business’s quarterly revenue was up 55.5% on a year-over-year basis. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the company. US Bancorp DE grew its stake in shares of Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after acquiring an additional 166 shares during the period. Glenmede Trust Co. NA grew its stake in Kymera Therapeutics by 3.6% in the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after buying an additional 235 shares in the last quarter. Cetera Investment Advisers raised its holdings in Kymera Therapeutics by 7.5% during the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after acquiring an additional 252 shares during the period. Larson Financial Group LLC lifted its position in shares of Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after acquiring an additional 287 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Kymera Therapeutics by 0.3% during the first quarter. Swiss National Bank now owns 94,500 shares of the company’s stock worth $7,871,000 after acquiring an additional 300 shares in the last quarter.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

Positive Sentiment: Kymera announced that enrollment in its Phase 2b BROADEN2 trial of KT-621 for moderate to severe atopic dermatitis was completed nearly six months ahead of schedule, with topline data expected by year-end 2026. The accelerated timeline also supports the company’s broader development plans for KT-621, including a planned Phase 3 start by mid-2027. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Positive Sentiment: BTIG Research reaffirmed its buy rating and set a $134 price target, implying additional upside if the clinical program continues to progress. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
Neutral Sentiment: The company also announced Felix J. Baker, Ph.D. as chairman of the board, a leadership change that may help support oversight but is less likely to move the stock on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
Negative Sentiment: Insider Noah Goodman sold 5,000 shares at $114 each, which can sometimes be viewed as a cautious signal, though the sale was relatively small versus his remaining holdings. Article: Insider transaction filing

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Jefferies Financial Group started coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 target price on the stock. UBS Group boosted their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $117.14.

Read Our Latest Stock Analysis on Kymera Therapeutics

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.